Histone deacetylase inhibitors (HDACi) developed as anti-cancer agents have a high
degree of selectivity for killing cancer cells. HDACi induce acetylation of histones and …

Protein acetylation is a reversible process regulated by histone deacetylases (HDAC) that is
often altered in human cancers. Suberoylanilide hydroxamic acid (SAHA) is the first HDAC …

Although DNA‐damaging agents are among the most effective anticancer drugs in clinical
use, their overall effectiveness is limited by the development of cross‐resistance to these …

This review focuses on the mechanisms of action of histone deacetylase (HDAC) inhibitors
(HDACi), a group of recently discovered 'targeted'anticancer agents. There are 18 HDACs …

Histone deacetylase inhibitors (HDACis) increase gene expression through induction of
histone acetylation. However, it remains unclear whether specific gene expression changes …

Histone deacetylase inhibitors (HDACIs) are a promising new class of anticancer drugs.
However, their mechanism of action has not been fully elucidated. Most studies have …

Histone deacetylases (HDACs) are enzymes involved in the remodelling of chromatin, and
have a key role in the epigenetic regulation of gene expression. In addition, the activity of …

This review focuses on the discovery and development of the histone deacetylase (HDAC)
inhibitor, suberoylanilide hydroxamic acid (SAHA). Post-translational modifications of the …

Histone deacetylase inhibitors (HDACi) are anti-cancer drugs that have moved rapidly
through clinical development and in 2006 vorinostat (SAHA, Zolinza) was given FDA …

Epigenic modifications, mainly DNA methylation and acetylation, are recognized as the main
mechanisms contributing to the malignant phenotype. Acetylation and deacetylation are …